卡地纳健康 2024年度报告

Dear Shareholders,Dear Shareholders, Fiscal 2025 was another strong year for Cardinal Health. We continued to accelerate ourmomentum with a relentless focus on driving simplification and operational efficienciesin our core, while investing for long-term growth. Our sustained performance is a resultof the progress we've made against our strategic priorities, as we continue evolving tomeet customer and patient needs while driving value creation for our shareholders.Fiscal 2025 was another strong year for Cardinal Health. We continued to accelerate ourmomentum with a relentless focus on driving simplification and operational efficienciesin our core, while investing for long-term growth. Our sustained performance is a resultof the progress we’ve made against our strategic priorities, as we continue evolving tomeet customer and patient needs while driving value creation for our shareholders. This fiscal year, we:This fiscal year, we: Delivered GAAP earnings per share of $6.45and non-GAAP diluted earnings per share of$8.24, growth of over 9%Delivered GAAP earnings per share of$6.45and non-GAAP diluted earnings per share of$8.24, growth of over9% Achieved segment profit growth of 22%for the year for the businesses reported as"Other" (Nuclear and Precision Health Solutions,at-Home Solutions and OptiFreight Logistics)Achieved segment profit growth of22%for the year for the businesses reported as“Other” (Nuclear and Precision Health Solutions,at-Home Solutions and OptiFreight Logistics) Grew Pharmaceutical and Specialty Solutionssegment profit by 12%Grew Pharmaceutical and Specialty Solutionssegment profit by12% Generated operating cash flow and non-GAAPadjusted free cash flow of $2.4 billion and$2.5 billion, respectivelyGenerated operating cash flow and non-GAAPadjusted free cash flow of$2.4 billionand$2.5 billion, respectively Achieved $135 million in segment profitand positive cash flow generation within theGlobal Medical Products and Distribution(GMPD) segment by continued executionof the multi-year improvement planAchieved$135 millionin segment profitand positive cash flow generation within theGlobal Medical Products and Distribution(GMPD) segment by continued executionof the multi-year improvement plan Returned approximately $1.25 billionto shareholders through dividends andshare repurchasesReturned approximately$1.25 billionto shareholders through dividends andshare repurchases The tremendous progress we've made is the result of our focus on continuousimprovement; as we outlined at our Investor Day' in June, we are seeing the positiveresults of the strong, resilient foundation we've built over the last several years.The tremendous progress we’ve made is the result of our focus on continuousimprovement; as we outlined at our Investor Day1in June, we are seeing the positiveresults of the strong, resilient foundation we’ve built over the last several years. Pharmaceutical and Specialty Solutions segment highlightsPharmaceutical and Specialty Solutions segment highlights for approximately $2.8 billion in cash, and the newly establishedUrology Alliance, following our recent acquisitions of UrologyAmerica and Potomac Urology. The Specialty Alliance providesadministrative and management services to physicians' practices,enabling providers to focus on patient care. The SpecialtyAlliance will also include Solaris Health, the country's leadingurology MSO, following the completion of the acquisition,for approximately $1.9 billion in cash, as announced in August.for approximately $2.8 billion in cash, and the newly establishedUrology Alliance, following our recent acquisitions of UrologyAmerica and Potomac Urology. The Specialty Alliance providesadministrative and management services to physicians’ practices,enabling providers to focus on patient care. The SpecialtyAlliance will also include Solaris Health, the country’s leadingurology MSO, following the completion of the acquisition,for approximately $1.9 billion in cash, as announced in August. The Pharmaceutical and Specialty Solutionssegment is our largest business, and we continueto prioritize its growth and resilience, strengtheningThePharmaceutical and Specialty Solutionssegmentis our largest business, and we continueto prioritize its growth and resilience, strengthening its core and expanding in Specialty.its core and expanding in Specialty. The new Consumer Health Logistics Center (CHLC) in CentralOhio is the first step in a multi-year plan to increase capacity anddrive efficiencies across our pharmaceutical distribution network.The CHLC, now fully operational, is a centralized replenishmentcenter for the distribution of over-the-counter medications,treatments and diagnostic solutions for our pharmacy customers.The newConsumer Health Logistics Center (CHLC)in CentralOhio is the first step in a multi-year plan to increase capacity anddrive efficiencies across our pharmaceutical distribution network.The CHLC, now fully operational, is a centralized re